Editorial: Treatment of malignant melanoma.
D000577:Amides / Q000627:therapeutic use; D000912:Antibodies, Neoplasm; D000917:Antibody Formation; D001500:BCG Vaccine / Q000627:therapeutic use; D002330:Carmustine / Q000627:therapeutic use; D002713:Chlorine / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007167:Immunotherapy; D008545:Melanoma / Q000188:drug therapy / Q000276:immunology / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D009578:Nitrobenzenes / Q000627:therapeutic use; D014226:Triazenes / Q000627:therapeutic use
D000577:Amides; D000912:Antibodies, Neoplasm; D001500:BCG Vaccine; D007093:Imidazoles; D007166:Immunosuppressive Agents; D009578:Nitrobenzenes; D014226:Triazenes; D002713:Chlorine; D002330:Carmustine